Publication number: 20220205039
Abstract: The application concerns means for determining the stage of hepatic tissue damage, in particular the hepatic fibrosis score of subjects infected with one or more hepatitis viruses. In particular, the means of the invention involve measuring the levels of expression of selected genes, said selected genes being: SPP1, and at least one gene from among A2M and VIM, and at least one gene from among IL8, CXCL10 and ENG, and optionally, at least one gene from among the list of the following sixteen genes: IL6ST, p14ARF, MMP9, ANGPT2, CXCL11, MMP2, MMP7, S100A4, TIMP1, CHI3L1, COL1A1, CXCL1, CXCL6, IHH, IRF9 and MMP1.
Type:
Application
Filed:
December 28, 2021
Publication date:
June 30, 2022
Inventors:
BÉNÉDICTE WATELET, TARIK ASSELAH, IVAN BIECHE, ISABELLE CATHERINE BATXELLI, NATHALIE JULLIAN, MICHEL VIDAUD, PATRICK MARCELLIN, DANIEL LAUNE, MOHAMMAD AFSHAR, EVE LAURE MATHIEU
Publication number: 20200056235
Abstract: The application concerns means for determining the stage of hepatic tissue damage, in particular the hepatic fibrosis score of subjects infected with one or more hepatitis viruses. In particular, the means of the invention involve measuring the levels of expression of selected genes, said selected genes being: SPP1, and at least one gene from among A2M and VIM, and at least one gene from among IL8, CXCL10 and ENG, and optionally, at least one gene from among the list of the following sixteen genes: IL6ST, p14ARF, MMP9, ANGPT2, CXCL11, MMP2, MMP7, S100A4, TIMP1, CHI3L1, COL1A1, CXCL1, CXCL6, IHH, IRF9 and MMP1.
Type:
Application
Filed:
August 28, 2019
Publication date:
February 20, 2020
Inventors:
BÉNÉDICTE WATELET, TARIK ASSELAH, IVAN BIECHE, ISABELLE CATHERINE BATXELLI, NATHALIE JULLIAN, MICHEL VIDAUD, PATRICK MARCELLIN, DANIEL LAUNE, MOHAMMAD AFSHAR, EVE LAURE MATHIEU
Patent number: 10435744
Abstract: The application concerns means for determining the stage of hepatic tissue damage, in particular the hepatic fibrosis score of subjects infected with one or more hepatitis viruses. In particular, the means of the invention involve measuring the levels of expression of selected genes, said selected genes being: SPP1, and at least one gene from among A2M and VIM, and at least one gene from among IL8, CXCL10 and ENG, and optionally, at least one gene from among the list of the following sixteen genes: IL6ST, p14ARF, MMP9, ANGPT2, CXCL11, MMP2, MMP7, S100A4, TIMP1, CHI3L1, COL1A1, CXCL1, CXCL6, IHH, IRF9 and MMP1.
Type:
Grant
Filed:
April 17, 2017
Date of Patent:
October 8, 2019
Assignees:
BIO-RAD EUROPE GMBH, ARIANA PHARMACEUTICALS, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
Inventors:
Bénédicte Watelet, Tarik Asselah, Ivan Bieche, Isabelle Catherine Batxelli, Nathalie Jullian, Michel Vidaud, Patrick Marcellin, Daniel Laune, Mohammad Afshar, Eve Laure Mathieu
Publication number: 20170283871
Abstract: The application concerns means for determining the stage of hepatic tissue damage, in particular the hepatic fibrosis score of subjects infected with one or more hepatitis viruses. In particular, the means of the invention involve measuring the levels of expression of selected genes, said selected genes being: SPP1, and at least one gene from among A2M and VIM, and at least one gene from among IL8, CXCL10 and ENG, and optionally, at least one gene from among the list of the following sixteen genes: IL6ST, p14ARF, MMP9, ANGPT2, CXCL11, MMP2, MMP7, S100A4, TIMP1, CHI3L1, COL1A1, CXCL1, CXCL6, IHH, IRF9 and MMP1.
Type:
Application
Filed:
April 17, 2017
Publication date:
October 5, 2017
Inventors:
BÉNÉDICTE WATELET, TARIK ASSELAH, IVAN BIECHE, ISABELLE CATHERINE BATXELLI, NATHALIE JULLIAN, MICHEL VIDAUD, PATRICK MARCELLIN, DANIEL LAUNE, MOHAMMAD AFSHAR, EVE LAURE MATHIEU
Patent number: 9624541
Abstract: The application concerns means for determining the stage of hepatic tissue damage, in particular the hepatic fibrosis score of subjects infected with one or more hepatitis viruses. In particular, the means of the invention involve measuring the levels of expression of selected genes, said selected genes being: SPP1, and at least one gene from among A2M and VIM, and at least one gene from among IL8, CXCL10 and ENG, and optionally, at least one gene from among the list of the following sixteen genes: IL6ST, p14ARF, MMP9, ANGPT2, CXCL11, MMP2, MMP7, S100A4, TIMP1, CHI3L1, COL1A1, CXCL1, CXCL6, IHH, IRF9 and MMP1.
Type:
Grant
Filed:
February 9, 2012
Date of Patent:
April 18, 2017
Assignees:
BIO-RAD INNOVATIONS, ARIANA PHARMACEUTICALS, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
Inventors:
Bénédicte Watelet, Tarik Asselah, Ivan Bieche, Isabelle Catherine Batxelli, Nathalie Jullian, Michel Vidaud, Patrick Marcellin, Daniel Laune, Mohammad Afshar, Eve Laure Mathieu
Publication number: 20130323720
Abstract: The application concerns means for determining the stage of hepatic tissue damage, in particular the hepatic fibrosis score of subjects infected with one or more hepatitis viruses. In particular, the means of the invention involve measuring the levels of expression of selected genes, said selected genes being: SPP1, and at least one gene from among A2M and VIM, and at least one gene from among IL8, CXCL10 and ENG, and optionally, at least one gene from among the list of the following sixteen genes: IL6ST, p14ARF, MMP9, ANGPT2, CXCL11, MMP2, MMP7, S100A4, TIMP1, CHI3L1, COL1A1, CXCL1, CXCL6, IHH, IRF9 and MMP1.
Type:
Application
Filed:
February 9, 2012
Publication date:
December 5, 2013
Applicant:
BIO RAD INNOVATIONS
Inventors:
Bénédicte Watelet, Tarik Asselah, Ivan Bieche, Isabelle Catherine Batxelli, Nathalie Jullian, Michel Vidaud, Patrick Marcellin, Daniel Laune, Mohammad Afshar, Eve Laure Mathieu
